Pedersen Oliver Heidmann, Larsen Mads Lamm, Kristensen Steen Dalby, Hvas Anne-Mette, Grove Erik Lerkevang
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Centre of Hemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Am J Case Rep. 2017 Sep 1;18:945-948. doi: 10.12659/ajcr.904148.
BACKGROUND Clopidogrel is commonly used in the prevention and treatment of cardiovascular events. However, despite clopidogrel treatment, some patients experience recurrent ischemic events. CASE REPORT We present the case of a 58-year-old man with polycythemia vera and concomitant thrombocytosis who suffered 6 episodes of cerebral infarctions and 1 myocardial infarction, despite treatment with clopidogrel. Following his last ischemic event, the antiplatelet therapy was intensified from initially clopidogrel monotherapy to dual antiplatelet therapy with aspirin 75 mg once daily and ticagrelor 90 mg twice daily. Since then, no cardiovascular event has been reported. CONCLUSIONS This case report illustrates that insufficient platelet inhibition with clopidogrel monotherapy in a patient with thrombocytosis may be associated with recurrent arterial thrombosis. The exact reasons for the insufficient platelet inhibition are not known, but a plausible explanation may be an accelerated platelet turnover reflected by an increased number of immature platelets in this patient.
氯吡格雷常用于预防和治疗心血管事件。然而,尽管接受了氯吡格雷治疗,一些患者仍会发生复发性缺血事件。病例报告:我们报告一例58岁男性真性红细胞增多症合并血小板增多症患者,尽管接受了氯吡格雷治疗,仍发生了6次脑梗死和1次心肌梗死。在他最后一次缺血事件后,抗血小板治疗从最初的氯吡格雷单药治疗强化为阿司匹林75mg每日1次和替格瑞洛90mg每日2次的双联抗血小板治疗。从那以后,未再报告心血管事件。结论:本病例报告表明,血小板增多症患者单用氯吡格雷时血小板抑制不足可能与复发性动脉血栓形成有关。血小板抑制不足的确切原因尚不清楚,但一个合理的解释可能是该患者未成熟血小板数量增加反映出的血小板更新加速。